433 related articles for article (PubMed ID: 17989444)
1. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
2. Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
Changolkar A; Menditto L; Shah M; Puto K; Farrelly E
Am J Health Syst Pharm; 2014 Apr; 71(7):562-9. PubMed ID: 24644116
[TBL] [Abstract][Full Text] [Related]
3. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
Farias-Eisner R; Horblyuk R; Franklin M; Lunacsek OE; Happe LE
Curr Med Res Opin; 2009 May; 25(5):1081-7. PubMed ID: 19298219
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Shorr AF; Kwong LM; Sarnes M; Happe L; Farrelly E; Mody-Patel N
Thromb Res; 2007; 121(1):17-24. PubMed ID: 17449088
[TBL] [Abstract][Full Text] [Related]
5. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
Happe LE; Farrelly EM; Stanford RH; Sarnes MW
J Thromb Thrombolysis; 2008 Oct; 26(2):125-31. PubMed ID: 18034323
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
9. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Migita K; Bito S; Nakamura M; Miyata S; Saito M; Kakizaki H; Nakayama Y; Matsusita T; Furuichi I; Sasazaki Y; Tanaka T; Yoshida M; Kaneko H; Abe I; Mine T; Ihara K; Kuratsu S; Saisho K; Miyahara H; Segata T; Nakagawa Y; Kamei M; Torigoshi T; Motokawa S
Arthritis Res Ther; 2014 Jul; 16(4):R154. PubMed ID: 25047862
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
Carson W; Schilling B; Simons WR; Parks C; Choe Y; Faria C; Powers A
J Pharm Pract; 2012 Apr; 25(2):180-9. PubMed ID: 21987527
[TBL] [Abstract][Full Text] [Related]
13. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
14. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
17. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
Wade WE; Spruill WJ
Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
[TBL] [Abstract][Full Text] [Related]
19. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
20. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
Argenta C; Ferreira MA; Sander GB; Moreira LB
Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
